# Francis Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/francis-medical

- Industry: Medical Devices & Equipment
- Headquarters: Maple Grove, US
- Website: www.francismedical.com
- Total disclosed funding: $70M
- Latest round: Series C (Dec 16, 2024)
- Investors on record: 7

## About

Francis Medical, Inc. is a US-based company focused on developing innovative urological cancer treatments, specifically utilizing advanced water vapor technology for prostate tissue ablation. Their aim is to minimize side effects while improving treatment outcomes.Founded in 2018 and headquartered in Maple Grove, US, Francis Medical, Inc. specializes in innovative solutions for urological cancers. The company has successfully completed 4 funding deals, with the recent Series C round on December 16, 2024, raising USD 40.00 mn. Key investors include Arboretum Ventures, Coloplast A/S, and Orlando Health Ventures. Michael Hoey is the founder of the company, and Mike Kujak serves as the CEO.Francis Medical focuses on the Vanquish® Water Vapor Ablation System, which employs sterile water vapor to precisely deliver thermal energy for the ablation of cancerous prostate tissue. This minimally invasive procedure seeks to reduce adverse effects common in traditional treatments, such as urinary incontinence and erectile dysfunction. The company aims to cater to prostate cancer patients across the United States and is also exploring potential applications for treating other urological cancers affecting the kidney and bladder.The revenue strategy of Francis Medical centers on the commercialization of its Vanquish Water Vapor Ablation System, targeting sales directly to hospitals and partnerships with urology clinics. The company anticipates establishing service agreements for training and supporting clinical use of the technology. The recent Series C funding of USD 40.00 mn reflects strong investor confidence in the company’s market entry strategy.Francis Medical plans to utilize the recent USD 40.00 mn Series C funding to support the VAPOR 2 pivotal clinical study and advance the U.S. commercialization of the Vanquish Water Vapor Ablation System for prostate cancer treatment. The company is exploring product enhancements and plans to enter additional markets as it scales its operations, with a focus on developing solutions for endourological cancers by 2025.

## Funding rounds

- Series C, Dec 16, 2024, $40M — Arboretum Ventures, Coloplast A/S, Solas BioVentures, Orlando Health Ventures, Tonkawa
- Series B, Sep 14, 2021, $20M — Arboretum Ventures, Coloplast A/S, Solas BioVentures, Tonkawa, H2oey Ventures, LLC
- Series A, Nov 16, 2018, $10M — Boston Scientific, Arboretum Ventures, Tonkawa, H2oey Ventures, LLC

## Investors

- Boston Scientific — Series A
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series A, Series B, Series C
- Tonkawa — Series A, Series B, Series C
- H2oey Ventures, LLC — Series A, Series B
- Coloplast A/S — Series B, Series C
- Solas BioVentures (https://capitalatlas.ai/funds/solas-bioventures) — Series B, Series C
- Orlando Health Ventures — Series C